Nasdaq:US$15.00 (-0.25) | HKEX:HK$23.38 (-0.58) | AIM:£2.20 (+0.01)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.